AKRO Insider Trading Activity and SEC Form 4 Filings
AKRO insider trading summary
No open-market insider purchases or sales of Akero Therapeutics, Inc. (AKRO) have been reported on SEC Form 4 in the past 12 months.
Latest AKRO insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 10, 2025 | Andrew Cheng | President and CEO | Sell | $1.6M (30,000 @ $53.98) |
| Oct 7, 2025 | Timothy Rolph | Chief Scientific Officer | Sell | $49K (1,037 @ $46.82) |
| Oct 7, 2025 | Timothy Rolph | Chief Scientific Officer | Sell | $527K (11,463 @ $46.01) |
| Oct 1, 2025 | Jonathan Young | Chief Operating Officer | Sell | $202K (4,201 @ $47.98) |
| Oct 1, 2025 | Jonathan Young | Chief Operating Officer | Sell | $395K (8,299 @ $47.64) |
| Sep 11, 2025 | Catriona Yale | Chief Development Officer | Sell | $28K (659 @ $43.02) |
| Sep 11, 2025 | William Richard White | Chief Financial Officer | Sell | $28K (659 @ $43.02) |
| Sep 11, 2025 | Timothy Rolph | Chief Scientific Officer | Sell | $24K (553 @ $43.02) |
| Sep 11, 2025 | Jonathan Young | Chief Operating Officer | Sell | $25K (586 @ $43.02) |
| Sep 11, 2025 | Andrew Cheng | President and CEO | Sell | $77K (1,796 @ $43.02) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.